

FIGURE 1




FIG. 1 shows the in vitro inhibition effect of a representative combination of the invention, Compound 4b with KRAS G12C inhibitor AMG510, in MIA PaCa-2 cells.

FIGURE 2




FIG. 2 shows the in vitro inhibition effect of a representative combination of the invention, Compound 4b with EGFR inhibitor Afatinib, in MIA PaCa-2 cells.

FIGURE 3




FIG. 3 shows the in vitro inhibition effect of a representative combination of the invention, Compound 4b with ERK1/2 inhibitor LY3214996, in MIA PaCa-2 cells.

FIGURE 4




FIG. 4 shows the in vitro inhibition effect of a representative combination of the invention, Compound 4b with ERK1/2 inhibitor BVD-523, in MIA PaCa-2 cells.

FIGURE 5




FIG. 5 shows the in vitro inhibition effect of a representative combination of the invention, Compound 4b with RAF inhibitor Encorafenib, in MIA PaCa-2 cells.

FIGURE 6




FIG. 6 shows the in vitro inhibition effect of a representative combination of the invention, Compound 4b with PRMT5 inhibitor Compound 24 of WO 2019116302, in MIA PaCa-2 cells.

FIGURE 7




FIG. 7 shows the in vitro inhibition effect of a representative combination of the invention, Compound 1 with EGFR inhibitor Afatinib, in MIA PaCa-2 cells.

FIGURE 8




FIG. 8 shows the in vitro inhibition effect of a representative combination of the invention, Compound 1 with KRAS G12C inhibitor AMG510, in MIA PaCa-2 cells.

FIGURE 9




FIG. 9 shows the in vitro inhibition effect of a representative combination of the invention, Compound 1 with ERK1/2 inhibitor LY3214996, in MIA PaCa-2 cells.

FIGURE 10




FIG. 10 shows the in vitro inhibition effect of a representative combination of the invention, Compound 1 with ERK1/2 inhibitor BVD-523, in MIA PaCa-2 cells.

FIGURE 11




FIG. 11 shows the in vitro inhibition effect of a representative combination of the invention, Compound 1 with RAF inhibitor Encorafenib, in MIA PaCa-2 cells.

FIGURE 12




FIG. 12 shows the in vitro inhibition effect of a representative combination of the invention, Compound 1 with PRMT5 inhibitor Compound 24 of WO 2019116302, in MIA PaCa-2 cells.

FIGURE 13




FIG. 13 shows the in vitro inhibition effect of a representative combination of the invention, Compound 6a with EGFR inhibitor Afatinib, in MIA PaCa-2 cells.

FIGURE 14




FIG. 14 shows the in vitro inhibition effect of a representative combination of the invention, Compound 6a with KRAS G12C inhibitor AMG510, in MIA PaCa-2 cells.

FIGURE 15




FIG. 15 shows the *in vitro* inhibition effect of a representative combination of the invention, Compound 6a with ERK1/2 inhibitor LY3214996, in MIA PaCa-2 cells.

FIGURE 16




FIG. 16 shows the *in vitro* inhibition effect of a representative combination of the invention, Compound 6a with ERK1/2 inhibitor BVD-523, in MIA PaCa-2 cells.

FIGURE 17




FIG. 17 shows the in vitro inhibition effect of a representative combination of the invention, Compound 5 with ERK1/2 inhibitor BVD-523, in MIA PaCa-2 cells.

FIGURE 18




FIG. 18 shows the in vitro inhibition effect of a representative combination of the invention, Compound 5 with ERK1/2 inhibitor LY3214996, in MIA PaCa-2 cells.

FIGURE 19




FIG. 19 shows the in vitro inhibition effect of a representative combination of the invention, Compound 5 with EGFR inhibitor Afatinib, in MIA PaCa-2 cells.

FIGURE 20




FIG. 20 shows the in vitro inhibition effect of a representative combination of the invention, Compound 5 with KRAS G12C inhibitor AMG510, in MIA PaCa-2 cells.

FIGURE 21




FIG. 21 shows the in vitro inhibition effect of a representative combination of the invention, Compound 5 with Compound 24 of WO 2019116302, in MIA PaCa-2 cells.

FIGURE 22




FIG. 22 shows the in vitro inhibition effect of a representative combination of the invention, Compound 2 with KRAS G12C inhibitor AMG510, in MIA PaCa-2 cells.

FIGURE 23




FIG. 23 shows the in vitro inhibition effect of a representative combination of the invention, Compound 3a with KRAS G12C inhibitor AMG510, in MIA PaCa-2 cells.

FIGURE 24




FIG. 24 shows the in vitro inhibition effect of a representative combination of the invention, Compound 3a with ERK1/2 inhibitor LY3214996, in MIA PaCa-2 cells.

FIGURE 25




FIG. 25 shows the in vitro inhibition effect of a representative combination of the invention, Compound 3a with RAF inhibitor Encorafenib, in MIA PaCa-2 cells.

FIGURE 26




FIG. 26 shows the in vitro inhibition effect of a representative combination of the invention, Compound 4b with pan-RAF inhibitor LXH254, in MIA PaCa-2 cells.

FIGURE 27




FIG. 27 shows the in vitro inhibition effect of a representative combination of the invention, Compound 4b with SHP2 inhibitor TNO155, in MIA PaCa-2 cells.

FIGURE 28




FIG. 28 shows the in vitro inhibition effect of a representative combination of the invention, Compound 7 with KRAS G12C inhibitor AMG510, in MIA PaCa-2 cells.

FIGURE 29




FIG. 29 shows the in vitro inhibition effect of a representative combination of the invention, Compound 7 with EGFR inhibitor Afatinib, in MIA PaCa-2 cells.

FIGURE 30




FIG. 30 shows the in vitro inhibition effect of a representative combination of the invention, Compound 7 with ERK1/2 inhibitor LY3214996, in MIA PaCa-2 cells.

FIGURE 31




FIG. 31 shows the in vitro inhibition effect of a representative combination of the invention, Compound 7 with ERK1/2 inhibitor BVD-523, in MIA PaCa-2 cells.

FIGURE 32




FIG. 32 shows the in vitro inhibition effect of a representative combination of the invention, Compound 7 with RAF inhibitor Encorafenib, in MIA PaCa-2 cells.

FIGURE 33




FIG. 33 shows the in vitro inhibition effect of a representative combination of the invention, Compound 7 with pan-RAF inhibitor LXH254, in MIA PaCa-2 cells.

FIGURE 34




FIG. 34 shows the in vitro inhibition effect of a representative combination of the invention, Compound 7 with SHP2 inhibitor TNO155, in MIA PaCa-2 cells.

FIGURE 35




FIG. 35 shows the in vitro inhibition effect of a representative combination of the invention, Compound 7 with KRAS G12C inhibitor MRTX849, in MIA PaCa-2 cells.

FIGURE 36




FIG. 36 shows the in vitro inhibition effect of a representative combination of the invention, Compound 7 with PI3K inhibitor BYL-719 in MIA PaCa-2 cells.

FIGURE 37




FIG. 37 shows the in vitro inhibition effect of a representative combination of the invention, Compound 7 with Type I PRMT inhibitor GSK3368715 in MIA PaCa-2 cells.

FIGURE 38




FIG. 38 shows the in vitro inhibition effect of a representative combination of the invention, Compound 7 with FGFR inhibitor Nintedanib in MIA PaCa-2 cells.

FIGURE 39




FIG. 39 shows the in vitro inhibition effect of a representative combination of the invention, Compound 7 with CDK4/6 inhibitor Abemaciclib in MIA PaCa-2 cells.

FIGURE 40





FIG. 40 shows the in vitro inhibition effect of a representative combination of the invention, Compound 7 with MRTX1133 in SW-1990 cells.

FIGURE 41



**FIG. 41** shows the in vitro inhibition effect of a representative combination of the invention, Compound 7 with Gemcitabine in MIA PaCa-2 cells.